ResearcherActive in the last 2 years

Katayoun Moini

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5081159763. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper

Papers 1

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. Co-author DOI 10.1093/oncolo/oyae267 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Patrick Soon‐Shiong · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗
Tara Elisabeth Seery · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗
Himanshu N. Brahmbhatt · 1 shared paper, 2025 · strength 0.27
- Paper Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. DOI 10.1093/oncolo/oyae267 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.